Global pharmaceutical company Eli Lilly (NYSE:LLY) in Q4 CY2024, with sales up 44.7% year on year to $13.53 billion. The company’s full-year revenue guidance of $59.5 billion at the midpoint ...

The post Eli Lilly cuts Q4 sales forecast, but analyst remains bullish on stock—here’s why appeared first on Invezz Eli Lilly and Company eli lilly co, eli lilly and company stock© Invezz ...

Eli Lilly is scheduled to release its Q4 earnings report next month, and analysts forecast triple-digit profit growth.

Eli Lilly's Q4 revenue surged 45% to $13.53 billion, fueled by Mounjaro and Zepbound. 2025 guidance forecasts up to $61 billion in sales, driven by new drug launches.

Eli Lilly's strong momentum in blockbuster therapies and promising pipeline signals future growth, but competition and pricing challenges loom. See more here.

Eli Lilly and Company's impressive Q4 earnings driven by tirzepatide's success, diverse portfolio, and promising pipeline. Click for my LLY stock update.

Eli Lilly’s revenue of $13.5 billion reflected a solid 45% y-o-y growth, thanks to the high demand for its obesity drug – Zepbound – which garnered $1.9 billion in sales.

Eli Lilly And Co (NYSE:LLY) will announce its fourth-quarter 2024 financial results and 2025 financial guidance on February 6. As per data from Benzinga Pro, the Wall Street estimates sales of $13 ...

Eli Lilly logs massive Q4 revenue jump—but it's not just thanks to Mounjaro and Zepbound By Fraiser Kansteiner Feb 6, 2025 12:56pm Eli Lilly Mounjaro Zepbound GLP-1 ...

Good morning. Thank you for joining us for Eli Lilly and Company's Q4 2024 earnings call. I'm Mike Czapar, senior vice president of investor relations.